Automate Your Wheel Strategy on JNJ
With Tiblio's Option Bot, you can configure your own wheel strategy including JNJ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol JNJ
- Rev/Share 37.9433
- Book/Share 32.6431
- PB 5.7718
- Debt/Equity 0.0806
- CurrentRatio 1.0736
- ROIC 0.1293
- MktCap 453935290168.0
- FreeCF/Share 7.8498
- PFCF 23.8111
- PE 18.2162
- Debt/Assets 0.0331
- DivYield 0.027
- ROE 0.3269
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 4
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | JNJ | Daiwa Securities | Neutral | Outperform | -- | $203 | Oct. 20, 2025 |
| Upgrade | JNJ | Wells Fargo | Equal Weight | Overweight | -- | $212 | Oct. 3, 2025 |
| Upgrade | JNJ | Guggenheim | Neutral | Buy | -- | $206 | Sept. 23, 2025 |
| Upgrade | JNJ | Erste Group | Hold | Buy | -- | -- | July 23, 2025 |
| Downgrade | JNJ | Leerink Partners | Outperform | Market Perform | -- | $153 | May 13, 2025 |
| Resumed | JNJ | BofA Securities | -- | Neutral | -- | $166 | Dec. 10, 2024 |
News
Johnson & Johnson (JNJ) Presents At 2025 Wells Fargo Healthcare Conference (Transcript)
Published: September 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Johnson & Johnson (NYSE:JNJ ) 2025 Wells Fargo Healthcare Conference September 3, 2025 11:50 AM EDT Company Participants Tim Schmid - Executive VP & Worldwide Chairman of MedTech Conference Call Participants Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Presentation Larry Biegelsen Senior Medical Device Equity Research Analyst Okay. Are we ready to go.
Read More
J&J Gears Up for Some Key New Drug Approvals and Launches
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ believes 10 of its new products and pipeline candidates can deliver peak sales of $5 billion, including Talvey, Tecvayli, Imaavy, Caplyta and others.
Read More
J&J Ends Imaavy Development in Rheumatoid Arthritis Post Study Failure
Published: August 29, 2025 by: Zacks Investment Research
Sentiment: Neutral
JNJ halts Imaavy's rheumatoid arthritis program after trial results showed no added benefit over existing therapy.
Read More
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
Published: August 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
2 High-Conviction Picks For 7.73% Growth And 4.22% Yield Within A Dividend Portfolio
Published: August 26, 2025 by: Seeking Alpha
Sentiment: Positive
Through our latest additions of Deutsche Post and Meta Platforms to The Dividend Income Accelerator Portfolio, we have increased the portfolio's sector diversification and global exposure. In addition to that, we have increased the portfolio's potential for dividend growth and capital appreciation. Our portfolio balances income and dividend growth, reflected in the portfolio's Weighted Average Yield on Cost [TTM] of 4.22% and 5-Year Weighted Average Dividend Growth Rate [CAGR] of 7.73%.
Read More
J&J Stock Trading Above 200 & 50 Day SMA for 2 Months: Time to Buy?
Published: August 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson stock surges above key moving averages as strong results, raised guidance and growth prospects fuel momentum.
Read More
Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now
Published: August 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Read More
4 Medical Devices Behemoths to Buy Amid Extensive AI Applications
Published: August 22, 2025 by: Zacks Investment Research
Sentiment: Positive
AI-driven innovations in medical devices are fueling growth for BSX, JNJ, GEHC and TEM.
Read More
A new pharma factory shows how hard it could be for drugmakers to outrun Trump's tariffs
Published: August 21, 2025 by: CNBC
Sentiment: Positive
Fujifilm Biotechnologies will open a new biologics manufacturing plant in the U.S. this fall, with Regeneron and Johnson & Johnson as the initial customers. The Holly Springs, North Carolina, site is five years and $3.2 billion in the making.
Read More
Johnson & Johnson announces $2 billion investment to boost U.S. manufacturing as tariffs loom
Published: August 21, 2025 by: Fast Company
Sentiment: Positive
Johnson & Johnson said on Thursday it would invest $2 billion in North Carolina as it aims to expand its U.S. manufacturing presence amid looming drug import duties proposed by President Donald Trump's administration.
Read More
Can J&J Navigate Stelara, Talc Suits, Tariff & Other Headwinds?
Published: August 21, 2025 by: Zacks Investment Research
Sentiment: Negative
J&J battles Stelara losses, talc lawsuits, tariffs and China headwinds while banking on growth plans and new launches to stay resilient.
Read More
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
Published: August 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm
Published: August 17, 2025 by: The Motley Fool
Sentiment: Negative
Pharmaceutical companies regularly encounter substantial headwinds. Among the most significant are patent cliffs -- when therapies lose patent exclusivity, inviting cheaper generic or biosimilar competition that erodes their market share.
Read More
Why Is Johnson & Johnson (JNJ) Up 7.2% Since Last Earnings Report?
Published: August 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?
Read More
Back To Basics: Why I Favor Amgen Over Johnson & Johnson
Published: August 14, 2025 by: Seeking Alpha
Sentiment: Positive
Both Amgen (AMGN) and Johnson & Johnson (JNJ) recently received a 60-day ultimatum to lower their prices in the U.S. market. A fundamental analysis shows AMGN to be better positioned than JNJ to absorb drug pricing pressure. Both companies have robust profitability and R&D pipelines, but AMGN's growth record and PEGY ratio make it more appealing under current conditions.
Read More
J&J's MedTech Unit Sales Improve in Q2: Will the Upside Continue?
Published: August 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson's Q2 MedTech sales beat estimates, fueled by cardiovascular gains, surgical vision growth and new product momentum.
Read More
3 Big Dividend Plays With Strong Earnings to Back Them
Published: August 11, 2025 by: MarketBeat
Sentiment: Positive
Long-term dividend plays tend to be more stable than many other stocks—after all, this stability is why they are able to provide consistent dividends in the first place. Traditional dividend stocks are large, well-established companies that are unlikely to experience significant volatility apart from trends affecting the broader market.
Read More
Worried About a Fading Rally? Consider These 3 Dividend Stocks
Published: August 11, 2025 by: MarketBeat
Sentiment: Negative
Investors have checked plenty of boxes off their 2021 market bingo cards lately: a V-shaped recovery in the S&P 500 after a quick bear market, a wild cryptocurrency rally, and beaten-down meme stocks generating short squeezes.
Read More
Bet on JNJ & Hold on to Apple to Grow Your Retirement Fund Stress-Free
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ offers resilience and income, while Apple fuels long-term growth???ideal picks for a stress-free retirement portfolio.
Read More
Why Johnson & Johnson (JNJ) is a Top Dividend Stock for Your Portfolio
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Read More
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
J&J Expects Better Top-Line Growth in 2H: Can It Achieve the Goal?
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ lifts 2025 sales and EPS outlook on strong Q2 results, with new drug launches and MedTech gains fueling momentum.
Read More
4 Very Safe Dividend Stocks on Goldman Sachs' August Conviction Buy List
Published: August 01, 2025 by: 24/7 Wall Street
Sentiment: Positive
Founded in 1869, Goldman Sachs is the world's second-largest investment bank by revenue and is ranked 55th on the Fortune 500 list of the largest U.S.
Read More
JNJ or AZN: Which Pharma Giant is a Better Buy Post Q2 Results?
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ edges out AZN following Q2 results with raised guidance, stronger estimate revisions and a more attractive valuation.
Read More
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
Published: August 01, 2025 by: Benzinga
Sentiment: Positive
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Read More
5 Dogs of the Dow Are Crushing the S&P 500 and Nasdaq in 2025
Published: July 28, 2025 by: 24/7 Wall Street
Sentiment: Neutral
The Dogs of the Dow is a well-known strategy first published in 1991 by Michael O'Higgins.
Read More
US FDA says J&J's Ethicon issues correction related to surgical stapler
Published: July 25, 2025 by: Reuters
Sentiment: Negative
The U.S. drug regulator said on Friday Ethicon Endo-Surgery, a unit of Johnson & Johnson , issued a correction for certain lots of a part related to its surgical stapler and classified the action as "most serious".
Read More
Why Johnson & Johnson (JNJ) is a Top Momentum Stock for the Long-Term
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
J&J Innovative Medicine Unit Shines Again in Q2: Will This Continue?
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ's Innovative Medicine unit posts solid Q2 growth despite Stelara's LOE, powered by Darzalex, Tremfya, Erleada and new drugs.
Read More
Johnson & Johnson Stock Could Be Waking Up
Published: July 22, 2025 by: Seeking Alpha
Sentiment: Positive
Johnson & Johnson's stock appears undervalued, as sluggish revenue growth and margin contraction are offset by raised full-year guidance and a rebounding outlook. Both Innovative Medicine and MedTech segments show promising pipeline developments, with MedTech's growth and robotics ambitions offering future upside. Despite a dip in free cash flow, J&J's dividend remains attractive, with a solid 3.18% yield and a 62-year growth streak, supporting shareholder returns.
Read More
About Johnson & Johnson (JNJ)
- IPO Date 1943-01-02
- Website https://www.jnj.com
- Industry Drug Manufacturers - General
- CEO Joaquin Duato
- Employees 138100